Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00

Protagonist Therapeutics (NASDAQ:PTGX) had its price target upped by Barclays from $108.00 to $113.00 in a report issued on Thursday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Other equities research analysts have also issued research reports about the company. Citizens Jmp boosted their price objective on Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research report on Thursday. Weiss Ratings downgraded Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Citigroup boosted their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.31.

Protagonist Therapeutics Price Performance

PTGX stock opened at $92.08 on Thursday. The stock has a market cap of $5.88 billion, a price-to-earnings ratio of -44.92 and a beta of 2.26. The company has a 50 day simple moving average of $84.24 and a 200 day simple moving average of $77.02. Protagonist Therapeutics has a 1 year low of $35.97 and a 1 year high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.50%. On average, equities research analysts anticipate that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, Director Lewis T. Williams sold 18,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total value of $1,483,560.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Asif Ali sold 46,203 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the sale, the chief financial officer owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. This trade represents a 43.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 203,167 shares of company stock worth $16,889,199. Company insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PTGX. Farther Finance Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new stake in Protagonist Therapeutics during the fourth quarter worth approximately $27,000. Bessemer Group Inc. increased its holdings in Protagonist Therapeutics by 171.0% in the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after purchasing an additional 318 shares in the last quarter. Salomon & Ludwin LLC acquired a new position in Protagonist Therapeutics in the third quarter valued at approximately $29,000. Finally, CWM LLC boosted its holdings in shares of Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after buying an additional 407 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

More Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS view to $4.18 (from $3.40) and sharply boosted the Q3 2026 estimate to $3.60 (from $0.05), signaling stronger near‑term profit expectations that likely support today’s upside. MarketBeat PTGX
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $117 price objective — a positive endorsement that can attract momentum buyers and institutional attention. MarketBeat PTGX
• Neutral Sentiment: Modest near‑term estimate tweaks: Q1 2026 EPS was nudged from ($0.71) to ($0.70) and Q2 2026 was trimmed slightly to $1.98 (from $2.03) — small adjustments that are unlikely to move fundamentals materially on their own. MarketBeat PTGX
• Neutral Sentiment: Benzinga published an analyst roundup summarizing expert views on Protagonist, helpful for context but not a single‑catalyst item. A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts
• Negative Sentiment: HC Wainwright cut several multi‑year estimates sharply: FY2027 to ($2.06), FY2028 to ($2.08) (from +$0.40), FY2029 to $0.12 (from $4.56) and FY2030 to $1.22 (from $5.40). These downgrades introduce longer‑term earnings uncertainty and could limit sustained upside absent confirming clinical/commercial catalysts. MarketBeat PTGX
• Negative Sentiment: HC Wainwright also revised Q4 2026 from a previously higher figure to ($0.71), a notable near‑term miss relative to their prior view that may reflect timing or one‑off items in the model. MarketBeat PTGX

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.